BTIG upgraded Progyny (PGNY) to Buy from Neutral with a $28 price target The firm says the company’s demand is coming back up, the stock’s valuation is reasonable, and that it likes Progyny’s balance sheet and cash flow. BTIG’s recent survey of 15 health plans shows that Progyny is expected to gain “significant” market share, plans generally view the company as being high-quality with reasonable pricing, and that the company can improve overall cost trend, the analyst tells investors in a research note. BTIG believes consumption of services will continue to stabilize and improve, the Trump Administration favors in vitro fertilization, and election-related economic uncertainty is now behind us.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny upgraded to Buy from Neutral at BTIG
- Progyny launches Parent and Child Well-being Offering
- Progyny’s Promising Growth Amidst Uncertainty: Hold Rating Maintained
- Progyny, Inc. Reports Strong 2024 Earnings with Optimistic Outlook
- Progyny’s Strong Q4 Results Amid Competitive Challenges and Uncertain Demand: Hold Rating Maintained